Commercialization: Page 15
-
PharmaVoice Team/PharmaVoice
Personal Technology and Artificial Intelligence Will Provide for Better Health Outcomes
More and more, pharmaceutical companies are continuing to leverage wearable technology to not only track patient information and vitals, but also track their behavior over time. When a patient’s vitals are taken at a medical facility, only a brief window of data is recorded and monitored. With we...
By Juan Garcia • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Telehealth: Ready or Not — <del>Here it Comes</del>… It's Here to Stay
Our world is changing more rapidly than ever before, but certain constants remain imperative in the healthcare arena — human connection and access to education. Healthcare professionals (HCPs) need to be able to connect with their patients to properly assess their conditions. HCPs need access to ...
By Christine Molbury • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
The Next Chapter for Real World Evidence: Validating Data with the Patient Voice
In June 2020, in accordance with the 21st Century Cures Act of 2016 and the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) launched Project Patient Voice. This patient-focused drug development initiative facilitates systematic approaches to collecting and usin...
By Ramita Tandon • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
COVID-19: Silver Linings
COVID-19 has stretched our industry to adjust to all types of new “normals," yet amid all of the disruption and loss of life, there are pockets of light that are expected to lift the life sciences and its people to new heights. Of all the industries that have been impacted across the globe, the l...
By Taren Grom • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Age of the Machine: The Expanded Role of AI in Pharma
AI and machine learning have the potential to transform the life-sciences industry, but barriers around implementation, process, and regulatory uncertainty must be overcome first. Artificial intelligence and machine learning are very much part of the pharmaceutical landscape today and are expecte...
By Kim Ribbink • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Breaking Glass: Driving Diversity, Equity, and Inclusion
As companies grapple with an emotional year in terms of the pandemic and racial inequality, efforts to address diversity and inclusion are gaining momentum. When Joe Biden and Kamala Harris won the 2020 U.S. presidential election, it signaled a huge leap forward for diversity: the first woman Vic...
By Kim Ribbink • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Commanders & Chiefs: Chief Experience Officers
Chief experience officers are influencing the strategic direction of their companies to address the needs and wants of their customers. Julie Adrian Customer Focus “Get closer than ever to your customers. So close that you tell them what they need well before they realize it themselves." This quo...
By PharmaVoice Team • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
What Life Sciences Leaders Say During the Pandemic: 10 Key Takeaways
We are in a global pandemic that is exposing major issues in the commercial environment in which healthcare companies operate, with changes that are completely altering the landscape for the long term. Our 3rd Annual Leaders in Life Sciences Roundtable consisted of eight industry leaders with div...
By Edward John Allera • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Is the industry ready for an AI revolution? We hooked into AI’s potential impact on the life-sciences industry a couple of years ago. We were early enthusiasts, but by no means the first to grasp the importance of the technology on everything from drug innovation to commercial strategies. We even...
By Taren Grom • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Upfront
Takeda’s Innovators in Science Award Takeda Pharmaceuticals and the New York Academy of Sciences are drawing attention to the urgent needs of patients worldwide affected by an estimated 7,000 rare diseases. The 2020 Innovators in Science Award recognizes scientists from around the globe for their...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
HealthTech
Organ-on-a-Chip Transforms Drug Development Trend Watch: Healthtech Applications Run the Gamut from Chip Technology to EHRs, to Electronic Skin and Clinical Trials Draper’s Ex Vivo Immuno-oncology Dynamic Environment for Tumor biopsies (EVIDENT) is a microfluidic platform that maintains tumor fra...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
BenevolentAI Validates Baricitinib as Treatment for COVID-19 Trend Watch: AI solutions span counseling, selfies, biopsies and drug discovery London-based BenevolentAI has reported that data released from a large scale randomized clinical trial, sponsored by the National Institute of Allergy and ...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Creative Executions
Creative thinking inspires ideas. Ideas inspire change. — Barbara Januszkiewicz In the new-ish omnichannel world of advertising that includes print, TV, social media, etc., great creative based on great ideas, good data, and a fearless approach to ideation is the lynchpin that leads to great camp...
By Taren Grom • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Commercial Influencers
Influencers have the power to positively change the status quo because of their authority, knowledge, position, or relationship with their audience. According to the global consultancy Evaluate, the impact of COVID-19 has so far wiped $7.85 billion off forecasts for biopharma sales in 2020, with ...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Roshawn Blunt — Optimizing a Strategic Plan
Given cell and gene therapies are typically personalized medicines, they come with outlier pricing and other unique commercialization challenges that differ from other large and small molecule therapies. Roshawn Blunt, a respected biotech consultant, was inspired by President John Adams, who in 1...
By Roshawn Blunt • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Greg Skalicky — Understanding the Commercial Lifecycle
By building a complete commercial platform, we are able to take a broad view of how market and product complexities impact operations. With a wide breadth of clinical and commercial experience, Greg Skalicky, chief revenue officer of EVERSANA, has a keen understanding of the entire product lifecy...
By Greg Skalicky • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Artificial Intelligence: Driving Drug Innovation With AI
The global AI market has been showing rapid growth as major pharmaceutical and medical technology companies invest heavily in internal and external AI partnerships. According to some reports, more than 50% of executives expect broad scale AI adoption by 2025. Further, revenue generated through AI...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Case Study: Leveraging AI for Meaningful Clinical Trials
Clinical trial sponsors seeking to develop new drugs and therapies face unique challenges, particularly when it comes to understanding patient dosing and response to therapy. This aspect can be difficult, as patients often: Do not take their medicine regularly, or at all Take creative measures to...
By Rich Christie • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
How AI Can Improve Understanding of Patient's Behavior and Symptoms
Running and managing clinical trials, at the most basic level, is about creating a foundation to get the best possible data. While a great deal of thought goes into recruiting the right patients and developing the most effective protocols, initiatives designed to improve the experience for the pa...
By Michelle Marlborough • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
5 Steps to Intelligent Omnichannel Engagement
The future of HCP engagement in the post-pandemic world isn’t clear. But in the wake of pharma’s forced digital migration, the need for an effective omnichannel strategy is. Luckily, most commercial teams already have a strong data and analytics infrastructure in place and are beginning to activa...
By Matthew Van Wingerden • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Technology-Driven Pharmacovigilance Operations
Improving Data Quality and Compliance while Reducing Cost with AI Traditionally, the pharmacovigilance (PV) function has been responsible for collecting, assessing, and reporting safety information to health authorities, sites, and other stakeholders. Companies have invested in safety systems to ...
By Dinesh Kasthuril • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
AI and Drug Discovery
Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
The Accessibility of AI: Innovation at Your Fingertips
The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
AI-Driven Marketing
We have all seen those digital banners that are somehow related to what we’re looking at online and appear to follow us wherever we are. Don’t worry, there is nothing ominous at play and the government is not listening to our conversations through our devices. But this is not completely coinciden...
By J.P. Maranzani • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Leveraging AI to Slingshot Drugs from Lab to Market
The science of clinical development continually astounds even those of us intimately connected to it. We recognize that our overarching industry mandate — to develop and deliver safe and effective new therapies to fight and cure disease — must be continually informed by new thinking and tools if ...
By Malai Sankarasubbu • Oct. 1, 2020
Previous
